Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

11 août 2026 mis à jour par: BrainJuice

This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.

Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

30

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89101
        • Citruslabs

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Be male or female
  • Be aged 18-57
  • Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease
  • If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
  • Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
  • Willing to maintain the same diet and exercise regimen consistently throughout the study duration
  • Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
  • Resides in the United States
  • Has access to a computer or tablet device

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
  • History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
  • History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
  • History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
  • Anyone with a job that involves shift work that may be overnight or night hours
  • Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
  • Anyone with any allergies or sensitivities to any of the study product ingredients
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
  • Anyone unwilling to follow the study protocol
  • Anyone with a history of substance abuse
  • Anyone who is currently a smoker or has been a smoker in the past 3 months
  • Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: BrainJuice Supplement
Complément alimentaire: BrainJuice Supplement
All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Cognitive Assessment Score (Polygons)
Délai: Baseline, Week 2, Week 4, and Week 6
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Double Trouble)
Délai: Baseline, Week 2, Week 4, and Week 6
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Feature Match)
Délai: Baseline, Week 2, Week 4, and Week 6
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Paired Associates)
Délai: Baseline, Week 2, Week 4, and Week 6
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Digit Span)
Délai: Baseline, Week 2, Week 4, and Week 6
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Spatial Planning)
Délai: Baseline, Week 2, Week 4, and Week 6
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Self-Reported Focus
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Attention
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Concentration
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Productivity
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Alertness
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Clarity
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mood
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Fatigue
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Motivation
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Organization
Délai: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived organization from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

BrainJuice

Collaborateurs

Citruslabs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 novembre 2025

Achèvement primaire (Réel)

6 février 2026

Achèvement de l'étude (Réel)

6 février 2026

Dates d'inscription aux études

Première soumission

11 août 2026

Première soumission répondant aux critères de contrôle qualité

11 août 2026

Première publication (Réel)

14 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

14 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 20807 (Autre identifiant: Fred Hutch/University of Washington Cancer Consortium)
  • legacy-20807

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner